Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
January 11 2024 - 8:00AM
Business Wire
Brings 20+ years of experience in finance and
business operations at both public and private life sciences
companies
Bone Biologics Corporation (“Bone Biologics” or the
“Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic
products for spine fusion markets, today announced that effective
immediately Robert E. Gagnon has been named to the Company’s board
of directors. Mr. Gagnon fills the seat left by Erick Lucera, who
has resigned effective upon Mr. Gagnon’s appointment. The number of
directors of Bone Biologics remains at four.
Mr. Gagnon is currently chief financial officer of Remix
Therapeutics, a clinical stage company focused on small
molecule-mediated reprogramming of RNA processing to address
hard-to-drug disease drivers.
“We are delighted that a professional of Rob’s stature has
agreed to join our board of directors,” said Jeffrey Frelick,
president and chief executive officer of Bone Biologics. “He has
supported the growth of so many successful companies and we look
forward to Rob’s counsel. His experiences with clinical stage
companies, capital raising, and commercial organizations will be
particularly valuable as we undertake our pilot study with
NB-1."
Mr. Gagnon brings more than 20 years of financial and commercial
experience leading global finance operations. He served as an
Operating Partner at Gurnet Point Capital, a healthcare venture
capital and private equity fund. He was Chief Business Officer and
Chief Financial Officer at Verastem Oncology. Before that, he was
Chief Financial Officer at Harvard Bioscience, Inc. Mr. Gagnon
served as Executive Vice President, Chief Financial Officer, and
Treasurer at Clean Harbors, Inc. as well as Chief Accounting
Officer and Controller at Biogen Idec, Inc. Mr. Gagnon worked in a
variety of senior positions at Deloitte & Touche, LLP, and
PricewaterhouseCoopers, LLP. He holds an MBA from the MIT Sloan
School of Management and a BA in Accounting from Bentley
College.
Mr. Gagnon currently serves on the Board of Directors at
Verastem Oncology and Purple Biotech.
About Bone Biologics Bone Biologics was founded to pursue
regenerative medicine for bone. The Company is undertaking work
with select strategic partners that builds on the preclinical
research of the Nell-1 protein. Bone Biologics is focusing
development efforts for its bone graft substitute product on bone
regeneration in spinal fusion procedures, while additionally having
rights to trauma and osteoporosis applications. For more
information, please visit www.bonebiologics.com.
Forward-Looking Statements Certain statements contained
in this press release, including, without limitation, statements
regarding the expected results and performance of Mr. Gagnon with
the Company and the expected timing of enrollment in our pilot
study with NB-1, as well as statements containing the words “will,”
“prepare,” and words of similar import, constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve both
known and unknown risks and uncertainties. The Company’s actual
results may differ materially from those anticipated in its
forward-looking statements as a result of a number of factors,
including, but not limited to, market and other conditions and
risks generally associated with an undercapitalized developing
company, as well as the risks contained under “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022 and the Company’s other
filings with the Securities and Exchange Commission. Except as
required by applicable law, we undertake no obligation to revise or
update any forward-looking statements to reflect any event or
circumstance that may arise after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111829711/en/
LHA Investor Relations Kim Sutton Golodetz 212-838-3777
kgolodetz@lhai.com
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Sep 2023 to Sep 2024